stockrowWhat it does
Kodiak Sciences is a clinical-stage biotechnology company developing medicines for diseases of the retina, the light-sensitive tissue at the back of the eye. Founded in 2009 and headquartered in Palo Alto, it aims to prevent and treat causes of blindness. It had 124 employees in FY2025.
Its lead investigational medicine, Zenkuda, also called tarcocimab, is designed to block VEGF, a protein involved in retinal vascular disease. It is injected into the eye and is being developed for diabetic retinopathy, retinal vein occlusion and wet age-related macular degeneration. Kodiak’s goal is a medicine that can maintain effective drug levels in the eye for longer between treatments.
KSI-501, also investigational, targets both VEGF and IL-6, a protein associated with inflammation. It is being studied in wet age-related macular degeneration. KSI-101 targets the same two pathways and is being developed for macular edema, or retinal fluid, caused by inflammation. Both conditions can impair vision.
Zenkuda and KSI-501 use Kodiak’s Antibody Biopolymer Conjugate, or ABC, platform. The platform combines protein-based and chemistry-based approaches to drug design. KSI-101 is platform-independent. Kodiak is also developing an extension of its platform that incorporates small-molecule drugs, as well as an AI-enabled wearable headset for potential use in retina care. None of its product candidates has been approved for commercial sale.
How it makes money
Kodiak is precommercial. It has no products approved for sale and has not generated product revenue since inception. It has funded operations primarily by issuing common stock and selling rights to future royalties. Those sources of funding are not sales of its medicines.
The company’s objective is to develop its retina-focused candidates, seek FDA approval and ultimately commercialize them in major markets. It has retained global rights to make, use and sell its candidates. Kodiak intends to file a biologics license application for Zenkuda in diabetic retinopathy, retinal vein occlusion and wet age-related macular degeneration in 2026. The company plans to work with the FDA on timing so that the ongoing DAYBREAK study can be included if successful.
Zenkuda is designed as an eye-injected treatment. Kodiak’s objective, if it is approved, is a label allowing treatment intervals from 1-month through 6-month. KSI-501 and KSI-101 are also investigational medicines in clinical development. The company is advancing earlier programs for glaucoma and geographic atrophy, but those are not commercial products.
Before a new drug or biologic can be marketed, regulators generally require data on its quality, safety and efficacy and must approve the application. If a candidate is approved, Kodiak would also need patients, medical professionals and third-party payors to accept it. The company could face costs to build an independent commercialization organization, including sales, marketing and reimbursement capabilities. Kodiak has not established commercial product pricing or a recurring product-sales stream in the information available here.
Customers and how it sells
Kodiak’s intended patients are people with retinal diseases that can cause vision loss. Its Zenkuda program addresses diabetic retinopathy, retinal vein occlusion and wet age-related macular degeneration. KSI-501 is being studied in wet age-related macular degeneration, while KSI-101 is being developed for patients with retinal fluid caused by inflammation.
The candidates are being evaluated in clinical studies rather than sold as approved medicines. Retina specialists administer the type of eye injections used in the programs, and Kodiak’s DAYBREAK study uses a treatment approach based on retinal fluid as a marker of disease activity. For any approved product, acceptance by the medical community, patients and third-party payors would matter. Existing anti-VEGF medicines are widely used and broadly reimbursed by third-party payors.
Kodiak has retained global rights to its candidates and aims to commercialize them in major markets. It plans to seek FDA approval in the United States; commercialization outside the United States would also be subject to applicable foreign requirements. Kodiak’s DAZZLE study was a global, multicenter study. The company has no approved products for sale and has not generated product revenue since inception, so it does not have a disclosed product-customer concentration to describe.
Suppliers and costs
Kodiak works with contract manufacturer Lonza to supply its antibody biopolymer conjugate drug substance for clinical and commercial use. Together they planned Ursus, a custom-built facility dedicated to commercial-scale manufacture of Kodiak’s drug substance. Ursus was commissioned and received regulatory approval, and Kodiak released its first commercial-scale batch of tarcocimab in July 2023.
The agreement with Lonza covers Kodiak’s antibody biopolymer conjugate pipeline at clinical and commercial scales. It provides for manufacturing flexibility and allows for future process and equipment changes. Kodiak has also manufactured clinical material for KSI-501 and KSI-101 to support ongoing studies.
The company has devoted substantially all of its resources to discovering and developing candidates and manufacturing processes, building its platform and assembling drug-development capabilities. Clinical trials, regulatory work and manufacturing require spending before a product can be sold. Kodiak also identifies the potential cost of creating an independent commercial organization if it receives approval.
As of December 31, 2025, Kodiak had cash and cash equivalents of $209.9 million. The company believes that its cash and cash equivalents will support its current and planned operations into 2027.
Competitive position
Kodiak is developing treatments for markets where injected anti-VEGF medicines are already the standard of care. Established agents include Avastin, Eylea and Eylea HD, Vabysmo, Lucentis and its biosimilars. These medicines are widely used and broadly reimbursed by third-party payors.
Regeneron’s Eylea HD has FDA approvals in wet age-related macular degeneration, diabetic macular edema, diabetic retinopathy and retinal vein occlusion. In Phase 3 trials, it showed non-inferior visual acuity to standard-dose Eylea, with extended dosing intervals for many patients. Vabysmo has also shown non-inferior visual acuity outcomes against Eylea in Phase 3 trials across several retinal diseases.
Kodiak is seeking to compete partly through treatment durability. Zenkuda is designed to maintain effective drug levels in the eye for longer, while KSI-501 targets IL-6 as well as VEGF. The company also has a dedicated commercial-scale manufacturing facility and has retained global rights to its candidates.
Our reading: the ABC platform and clinical results offer a potential source of differentiation in dosing durability, but their competitive strength is not yet established in commercial use. Our reading: retained rights and dedicated manufacturing give Kodiak control over development and potential supply, though approval and market acceptance are still needed. The company also identifies a risk that its candidates or platform may not be sufficiently protected by intellectual property.
| Competitor | Where they compete | Threat (our reading) |
|---|---|---|
| Regeneron | Retinal diseases, including wet AMD, DME, DR and RVO | High |
Growth opportunities
Kodiak’s near-term development plans center on its late-stage retinal programs. Zenkuda has completed four Phase 3 pivotal studies that met their primary endpoints: GLOW1 and GLOW2 in diabetic retinopathy, BEACON in retinal vein occlusion and DAYLIGHT in wet age-related macular degeneration. Kodiak intends to file a biologics license application for those indications in 2026.
The ongoing DAYBREAK study evaluates both Zenkuda and KSI-501 against aflibercept in wet age-related macular degeneration. Enrollment is complete, and Kodiak expects topline results for the one-year primary endpoint in 3Q 2026. The company intends to work with the FDA on submission timing so that DAYBREAK can be included in Zenkuda’s application if the study succeeds.
For KSI-101, the PEAK and PINNACLE Phase 3 studies are enrolling patients with macular edema caused by inflammation. The studies cover patients with different levels of disease severity. Kodiak expects topline readouts in 4Q 2026 and 2Q 2027, respectively. It believes this condition represents a market segment separate from the established anti-VEGF market.
Further back in development, KSI-102 and KSI-103 target diseases of ocular inflammation and are progressing through pre-IND activities. Kodiak is also developing platform-based programs for glaucoma and geographic atrophy, designed to combine mechanisms of action with sustained release. Its VETi wearable headset has potential applications in retina care, alongside broader opportunities in identity security and cognitive sciences.
Structural risks
- Clinical results: Candidates may fail clinical studies, produce negative or inconclusive results, or be found to have harmful side effects. Zenkuda’s GLEAM and GLIMMER studies did not meet their primary efficacy endpoints, and the DAZZLE study also failed its primary endpoint and was discontinued.
- Regulatory approval: Kodiak depends on obtaining approvals before marketing its candidates. Regulators may require more costly or lengthy trials, impose clinical holds, or approve a product for narrower indications or patient groups than intended.
- Manufacturing: A candidate may not be capable of production in commercial quantities at an acceptable cost, or at all. Manufacturing, testing, release and import or export of sufficient stable quantities can also delay studies and regulatory submissions.
- Commercial acceptance: Even if a candidate is approved, patients, medical professionals or payors may not accept it as safe and effective. Kodiak may also be unable to establish the sales and marketing capabilities needed to gain market acceptance.
- Competition and intellectual property: Competitors could develop therapies or platform technologies that make Kodiak’s candidates or platform less competitive. The company’s candidates and platform may not be sufficiently covered by intellectual property under its exclusive rights, or may be covered by third-party rights.
Bottom line
Our reading
Our reading: Kodiak is a precommercial retinal-drug developer whose business depends on turning clinical programs into approved and accepted medicines. Its platform, retained rights and manufacturing facility provide a basis for commercialization, but those assets have not yet produced product revenue. Our reading: upcoming trial results and the planned Zenkuda application matter alongside the risk of further clinical setbacks, regulatory restrictions and competition from established treatments.